NEW YORK, July 11 – A Canadian consortium supported by GlaxoSmithKline has launched a proteomics study that will look at whether it is possible to use fruit flies to screen for human drugs.
Alan Bernstein, president of the Canadian Institutes of Health Research, Paul Lucas, president of GlaxoSmithKline, and Heather Munroe-Blum, vice president of research and international relations at the University of Toronto, said in a joint statement issued Tuesday that the $1.5 million, two-year study would search for novel ways to control proteins behavior.
The researchers hope that by studying the nuclear receptor family of the fruit fly, they will be able to gain new knowledge about human biology and disease.
"Today's announcement and partnership is another milestone in our ongoing commitment to support innovative Canadian research and development, encouraging the world's brightest researchers and scientists to conduct their important discovery work in Canada,” Lucas said.
The project is being funded through a partnership between GlaxoSmithKline and CIHR.
The participants in the project did not disclose where the research would take place and who would own the rights to the findings.